Dennis Chi, MD
Gynecologic Oncology · New York, NYNPI 1245215565
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Biom'up France SAS at 49.9% of the total. Reporting peaked in 2021 at $5,672 and has fallen 93.0% since, to $399 in 2025.
Across 15 payments — averaging $774.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biom'up France SAS$6K
- Biom'up SA$5K
- Medtronic$279
- Dilon Technologies, Inc.$175
- AstraZeneca$134
- Davol Inc.$57
- plus $15 from 1 others
What the payments were for
- Consulting fees$5,00043%
- Speaking & faculty fees$5,50047%
- Travel & lodging$2342%
- Food & beverage$8808%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biom'up France SAS | 5 | $5,797 |
| Biom'up SA | 4 | $5,157 |
| Medtronic | 2 | $279 |
| Dilon Technologies, Inc. | 1 | $175 |
| AstraZeneca | 1 | $134 |
| Davol Inc. | 1 | $57 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HemoBlast Bellows$5,972
- HEMOBLAST$5,000
- TruClear$279
- LYNPARZA$134
How this compares
$11,614 in reported general payments places this provider in the 85th percentile of 154 gynecologic oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin Sulfate | 24 | $99 |
| Metronidazole | 24 | $40 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in New York
- Bhavana PothuriNew York$366K
- Mario LeitaoNew York$116K
- Konstantin ZakashanskyNew York$93K
- Evelyn CantilloNew York$79K
- Farr NezhatNew York$41K
- Kristen ZeligsNew York$38K
- Nimesh NagarshethNew York$33K
- Jeff LinNew York$30K
- Valentin KolevNew York$23K
- Jason WrightNew York$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.